Sandoz Agrees to Pay 43 States Up to 469 Million Over Generic Drug Pricing Claims
Sandoz reached an in-principle settlement on August 3, 2026, agreeing to pay $400 million to 43 states and territories over seven years starting in 2027, with earlier state settlements bringing the total to approximately $450 to $469 million depending on the source. The agreement covers alleged price coordination across more than 100 generic drugs and includes a separate $28.5 million payment to indirect resellers such as pharmacies and hospitals, though no direct payments to individual consumers are described. The settlement is not yet final, Sandoz admitted no wrongdoing, and a broader multistate antitrust trial against other generic drug manufacturers remains scheduled for 2027.